Isolation and characterization of bacteriophages from the human skin microbiome that infect Staphylococcus

Luca G Valente1,2,3, Melissa Pitton1,3, Monika Fürholz4

  • 1Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

FEMS Microbes
|June 19, 2023
PubMed

Insights

Researchers isolated novel bacteriophages from human skin to combat Staphylococcus epidermidis infections. These phages show promise for treating nosocomial infections and biofilm-related issues.

Area of Science:

  • Microbiology
  • Virology
  • Biotechnology

Background:

  • Nosocomial infections pose a significant threat, with Staphylococcus epidermidis being a common opportunistic pathogen.
  • Limited availability of lytic bacteriophages restricts phage therapy options against S. epidermidis.

Purpose of the Study:

  • To develop an efficient method for isolating bacteriophages from the human skin microbiome.
  • To characterize novel S. epidermidis phages for potential therapeutic applications.

Main Methods:

  • Utilized niche-specific S. epidermidis isolates from human skin for phage propagation.
  • Genetically characterized eight phage genomes, including novel sequences across major staphylococcal phage families.
  • Assessed phage host-range against diverse S. epidermidis strains and evaluated efficacy against biofilms.

Main Results:

  • Successfully isolated and propagated phages from human skin samples where S. epidermidis was present.
  • Identified six unique phage sequences belonging to Siphoviridae, Podoviridae, and Myoviridae families.
  • Characterized narrow host-range phages, with one demonstrating efficacy against S. epidermidis biofilms on catheters.

Conclusions:

  • The human skin microbiome is a viable source for novel S. epidermidis bacteriophages.
  • Newly isolated phages possess unique genetic elements and potential for therapeutic use, including biofilm disruption.
  • Further research into S. epidermidis-phage interactions is crucial for advancing phage therapy.